# Bausch Health Companies Inc. (BHC) Stock Analysis: A Closer Look at Its 6.36% Potential Upside

- Link: https://www.directorstalkinterviews.com/bausch-health-companies-inc-bhc-stock-analysis-a-closer-look-at-its-6-36-potential-upside/4121211708
- Published: 2025-08-12T10:40:02+01:00
- Author: Madison Wilson

Bausch Health Companies Inc. (NYSE: BHC), a prominent player in the healthcare industry,
has been making waves in the market with a current stock price of $6.66 and a market
capitalization of $2.48 billion. The company, headquartered in Laval, Canada, operates
across several key sectors, including gastroenterology, hepatology, neurology, dermatology,
and more. Given its diverse portfolio, Bausch Health is well-positioned in the specialty
and generic drug manufacturing industry.

Investors might be intrigued by Bausch Health’s price movement, with its 52-week
range fluctuating between $4.32 and $9.78. The stock’s recent price change of 0.91(
0.16%) suggests a degree of volatility, which can present both opportunities and
risks for investors. With an average analyst target price of $7.08, the stock shows
a potential upside of 6.36%, a figure that could attract those looking for short-
to mid-term gains.

Despite the absence of traditional valuation metrics such as P/E and PEG ratios,
Bausch Health presents an interesting case with its forward P/E ratio standing at
a remarkably low 1.56. This suggests that the market expects significant earnings
growth relative to the current price, an element that could be appealing for value-
focused investors.

Performance-wise, Bausch Health has demonstrated a revenue growth of 5.30%, with
an earnings per share (EPS) of 0.26. Perhaps more striking is the company’s substantial
free cash flow, amounting to over $1.34 billion. This robust cash flow position 
enables Bausch Health to reinvest in its operations, potentially driving further
growth and innovation.

However, investors should note the company’s dividend policy—or lack thereof. With
a payout ratio of 0.00%, Bausch Health does not currently offer dividends, which
may not suit income-focused investors. Instead, the company appears to be reinvesting
its earnings into expanding and strengthening its business segments, such as Salix
and Bausch + Lomb.

From an analyst perspective, Bausch Health has garnered a mixed sentiment. The stock
holds one buy rating, five hold ratings, and one sell rating, reflecting a cautious
but optimistic outlook. The target price range spans from $5.00 to $10.00, indicating
a wide spectrum of expectations regarding the company’s performance.

Technical indicators reveal that the stock is trading slightly above its 50-day 
moving average of $6.06 but below the 200-day moving average of $6.70. The Relative
Strength Index (RSI) of 80.23 suggests that the stock is currently overbought, which
may prompt some investors to exercise caution before entering new positions.

Bausch Health’s strategic focus on its diversified segments, especially in high-
demand areas such as eye health and gastroenterology, underscores its potential 
for sustained growth. As investors consider Bausch Health for their portfolios, 
weighing the potential upside against the inherent risks of the healthcare sector
is crucial. With its historical roots as Valeant Pharmaceuticals International, 
Inc., Bausch Health continues to evolve, offering investors a blend of stability
and opportunity in a dynamic market landscape.

Share on: